Shijiazhuang Yishengtang Medical Product Co., Ltd.
MORE +
Shijiazhuang Yishengtang Medical Product Co., Ltd.
MORE +
scroll down

PRODUCTS


Main products include intraoperative hemostasis, anti-adhesion materials, wound repair dressing, trauma first aid, daily protective repair and other products.

Stop Bleeding and Prevent Adhesion


When compression, binding or other routine hemostasis measures are ineffective or cannot be implemented during surgery, hemostasis of blood capillary, vein and arteriole in the body and bleeding of surgical wound.

VIEW MORE +

Wound Tissue Repair


It is applicable to the repair of human skin and open wounds, including burns, frostbite, trauma and ulcers. Can be washed, sprayed, wet applied...

VIEW MORE +

Trauma First Aid


It is applicable to emergency hemostasis of various traumatic bleeding (such as abrasion, vascular puncture, tube insertion, incision wound, etc.)

VIEW MORE +

Daily Protection and Repair


It is suitable for disinfection of intact skin, damaged skin and wound; It is applicable to disinfection of object surface and fabric.

VIEW MORE +

YISHENGTANG MEDICAL PRODUCT

For The Health Of Millions Of Lives

View Details
2004 Year

Established

35000 ㎡

Area Covered

22 million

Registered Capital

308 +

Company Staff

Corporate Culture


Our Vision

Be a leading enterprise of biomedical materials and create outstanding brands in the industry

View Details

Management Idea

User-oriented, quality first, lean production and safety first.

View Details

Management

Crisis awareness, set an example, be honest, do things with integrity, and attach importance to talents.

View Details

Working Philosophy

Absolute obedience, dedication, results-oriented, efficient implementation, and teamwork.

View Details

BLOG CENTER


2026

11-21

news

Wound Tissue Repair in 2026: Evidence-Based Clinical Protocols for Optimal Healing Outcomes

This 2026 evidence-based guide demystifies the biological mechanisms of wound tissue repair, evidence-aligned clinical management workflows, and the role of modern intraoperative hemostatic products in supporting optimal healing outcomes. Rooted in real-world clinical practice data from Yishengtang’s global medical partner network, the content breaks down common misconceptions, compares standard repair protocols, and provides actionable steps for clinicians to reduce complication rates for patients across surgical and trauma settings.

2026

11-20

news

Wound Tissue Repair 2026: Evidence-Based Protocols for Optimal Clinical Outcomes

This comprehensive guide to wound tissue repair synthesizes 2026 peer-reviewed clinical research, real-world surgical experience, and validated product application data to break down the full tissue healing lifecycle, from initial injury response to mature scar formation. We compare common repair strategies, highlight evidence-based intraoperative optimization steps, address frequently asked clinical questions, and outline measurable outcomes across different wound types, to help clinical teams select safe, effective repair pathways aligned with current global wound care consensus.

2026

11-19

news

Hemostasis and Adhesion Prevention: 2026 Surgical Product Guide

This 2026 guide explains hemostasis and adhesion prevention for surgeons, procurement teams, and medical device evaluators. It covers why intraoperative bleeding control and barrier placement matter, how modern absorbable products work, what clinical evidence suggests, and how to choose between gauze, oxidized cellulose, fibrin sealants, and dedicated adhesion barriers. The summary also highlights practical lessons from surgical case reviews and introduces Yishengtang’s intraoperative hemostasis product portfolio from www.sjzyst.com.

2026

11-18

news

Hemostasis and Adhesion Prevention: 2026 Clinical Guide

This guide explains the clinical meaning, mechanisms, product selection, and implementation steps of hemostasis and adhesion prevention in 2026. It compares common absorbable hemostatic agents and adhesion barriers, highlights practical experience from intraoperative use, and answers common surgeon questions about safety, timing, and outcomes. The goal is to help surgical teams choose materials that support both bleeding control and reduced adhesion formation.

2026

11-17

news

Hemostasis and Adhesion Prevention: 2026 Evidence-Based Surgical Guide

This 2026 evidence-based guide breaks down core clinical principles, implementation workflows, and product selection criteria for hemostasis and adhesion prevention across general, gynecological, and orthopedic surgical procedures. Drawing on 3 years of real-world surgical case data from Yishengtang clinical partners, the content compares traditional gauze-based methods with modern absorbable barrier products, outlines standardized on-surgery steps, and addresses common clinical pain points to reduce post-operative complication rates for patients.

2026

11-16

news

2026 Evidence Guide: Hemostasis and Adhesion Prevention Best Practices

This evidence-based 2026 guide breaks down integrated hemostasis and adhesion prevention strategies for general, obstetric, and minimally invasive surgical teams. We draw on 10+ years of clinical product deployment data, peer-reviewed surgical safety research, and real-world case observations to compare current product options, outline standardized implementation steps, and highlight key outcome metrics that drive lower post-surgical complication rates. Content is structured to support both surgical teams evaluating new protocols and procurement teams selecting high-value, clinically validated products.